PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 563953

Comparative pharmacologic effects on tissue factor activity in normal cells and an established cell line.

J R Maynard·D E Burkholder·D J Pizzuti
View original source ↗Export metadata ↓

Abstract

The tissue factor (thromboplastin) activity of cells grown in vitro is modulated by exogenous drugs. The activity of human foreskin fibroblasts and umbilical vein smooth muscle cells is enhanced by 10(-6) M hydrocortisone or 1 mM butyrate. Activity is suppressed in these cells by 10(-6) M colchicine whereas 10(-4) M chloroquine has little or no effect. Two established cell lines, WISH or HeLa cells, have elevated tissue factor activity in the presence of colchicine or chloroquine and suppressed activity with exogenous hydrocortisone. Their activity is also decreased by 10 mM butyrate whereas 1 mM butyrate does not alter activity. Colchicine and butyrate apparently act via a mechanism unrelated to their effect on microtubules since it is possible to dissociate activity changes from morphologic changes. Umbilical vein endothelial cell tissue factor activity responds uniquely to exogenous drugs. Hydrocortisone or 10(-5) M vinblastine (or colchicine) only minimally alters activity. Endothelial cells are not simply refractory toward all drugs, however, since chloroquine dramatically enhances activity whereas 1 mM butyrate suppresses it. The low specific activity of endothelial cells and their apparently unique drug response may be another measure of their function as an in vivo hemostatic barrier.

Explore related subjects

AmnionButyratesCell LineCells, CulturedChloroquineColchicineEndotheliumFibroblastsHeLa CellsHumansHydrocortisoneMaleMuscle, SmoothNucleotides, CyclicPenisThromboplastinUmbilical VeinsVinblastineComparative StudyJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J R Maynard, D E Burkholder, D J Pizzuti. 1978. Comparative pharmacologic effects on tissue factor activity in normal cells and an established cell line.. https://pubmed.ncbi.nlm.nih.gov/563953/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Parturition.

Explore the source record for details and available documents.

Amnion↗
PubMed2007

Intrathoracic pressure in congenital chylothorax: keystone for the rationale of thoracoamniotic shunting?

Thoracoamniotic shunting in fetal pleural effusion has poor results, with an overall survival of less than 50% when hydrops is associated. Those cases without hydrops presented the best evolution, but the indication in these cases remains controversial. We present a dichorionic diamniotic twin pregnancy at 29 weeks' with right pleural effusion and hydrops, in which one fetus presented diaphragm inversion and mediastinal shift, both considered as ultrasonographic signs of thoracic hypertension. A thoracoamniotic shunt reversed these signs immediately. Nevertheless, 1 week after, these signs and skin edema reappeared and the effusion increased, leading to a second thoracocenthesis for drainage and intrathoracic pressure measurement. Amniotic fluid and intrathoracic pressures were found at 21 and 39 mm Hg, respectively. A cesarean section was performed and the catheter was found to be obliterated by cellular detritus of leukocytes and fibrin. Our conclusion is that ultrasonographic signs of elevated thoracic pressure are a keystone for the shunt indication, and that this could be corroborated by direct measurements. This can be an important parameter for precise indication of thoracoamniotic shunting.

Amnion↗
PubMed2007

Rate of epithelialisation and re-operations in corneal ulcers treated with amniotic membrane transplantation combined with botulinum toxin-induced ptosis.

OBJECTIVE: To examine the efficacy of amniotic membrane transplantation (AMT) and/or botulinum toxin type A-induced ptosis (Dysport) in the treatment of corneal ulcerations of different entities. METHODS: Retrospective evaluation of 137 cases of corneal ulcers which have been treated with AMT, botulinum toxin type A and perforating keratoplasty (pKP). Regarding corneal ulcerations the patients were divided into three groups: group A, patients initially having received an AMT (92 eyes eventually followed by AMT or pKP as a second intervention); group B, patients initially having received an AMT (32 eyes followed by botulinum toxin type A injection in the upper lid as a second intervention); group C, patients initially treated only by botulinum toxin type A injection (13 eyes followed occasionally by AMT or pKP or additional botulinum toxin type A injection). Additionally, we analysed the complete epithelialisation rate of the ocular surface in respect to different ocular and systemic diseases and compared the frequency of re-operations in each group. RESULTS: The overall follow-up was 14.2 (+/-14.7 months; range from 1 to 60 months). The total frequency of re-operations was 45.3% (overall time until complete epithelialisation 12.7 (+/-6.1) days). If the patient was initially treated with an AMT (group A), the re-operation rate was 44.6%. Treating affected eyes in this group with a subsequent amniotic membrane resulted in a reduction of re-operation rate to 30.4%. In cases with induced ptosis by injecting botulinum toxin type A in the M. levator palpebrae (group B), the re-operation frequency could be reduced to 34.4% with similar times of epithelialisation [group A: 12.0 (+/-6.5) days and group B: 11.7 (+/-5.5) days]. In group C, with botulinum toxin type A alone initially, the re-operation rate of 69.2% was the highest one compared with groups A and B; this rate could be drastically reduced by a following AMT to 23.1%. Surprisingly, in the few successful cases with botulinum toxin type A alone a quite low epithelialisation time of 6.5 (+/-1.3) days was achieved, but turned out to be similar after additional interventions if compared with the other groups (botulinum toxin type A + AMT: 15.7 (+/-4.9) day). CONCLUSION: AMT alone and combined with botulinum toxin type A-induced ptosis is an effective surgical approach for managing severe corneal ulcerations by promoting wound healing and stabilizing ocular surface homeostasis.

Amnion↗